Mansanguan et al.'s Thai study: Do not forget this Thai study in teens (13 to 18 years, post 2nd dose) following Pfizer mRNA technology vaccine! n=314 teens, 13 lost, 301 final cohort; most common

cardiovascular signs, symptoms were tachycardia (7.6%), shortness of breath (6.6%), palpitation (4.3%), chest pain (4.3%), hypertension (4%). 2.3% elevated cardiac marker; 30% cardiac manifestation

https://www.mdpi.com/2414-6366/7/8/196

‘314 participants; of these, 13 participants were lost to follow-up, leaving 301 participants for analysis…

most common cardiovascular signs and symptoms were tachycardia (7.64%), shortness of breath (6.64%), palpitation (4.32%), chest pain (4.32%), and hypertension (3.99%).

One participant could have more than one sign and/or symptom. Seven participants (2.33%) exhibited at least one elevated cardiac biomarker or positive lab assessments.

Cardiovascular manifestations were found in 29.24% of patients, ranging from tachycardia or palpitation to myopericarditis.

Myopericarditis was confirmed in one patient after vaccination. Two patients had suspected pericarditis and four patients had suspected subclinical myocarditis.

In conclusion, Cardiovascular manifestation in adolescents after BNT162b2 mRNA COVID-19 vaccination included tachycardia, palpitation, and myopericarditis. The clinical presentation of myopericarditis after vaccination was usually mild and temporary, with all cases fully recovering within 14 days. Hence, adolescents receiving mRNA vaccines should be monitored for cardiovascular side effects.’